Broadly Neutralizing Antibodies for the Treatment and Prevention of HIV Infection

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2019 Nov 26

PMID 31764199

Citations 40

Authors

Marina Caskey

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Several anti-HIV-1 broadly neutralizing antibodies (bNAbs) with exceptional breadth and potency, and targeting different HIV-1 envelope epitopes have entered clinical trials. bNAbs are being evaluated for their potential as long-acting alternatives to antiretrovirals in HIV-1 prevention and therapy, and for potential role in strategies aiming at long-term viral remission. Here, we discuss recent findings from bNAb clinical studies.

Recent Findings: bNAbs targeting distinct HIV-1 envelope epitopes have shown, in general, favorable safety profiles, and engineered bNAb variants have demonstrated improved pharmacokinetics. Single bNAb infusions transiently decreased viremia with subsequent selection of escape variants, while a combination of two bNAbs successfully maintained viral suppression in individuals harboring antibody-sensitive viruses after antiretroviral therapy (ART) was discontinued. Studies in animal models suggest that bNAbs can modulate immune responses and potentially interfere with the establishment or composition of the latent reservoir, and ongoing clinical studies aim to assess potential bNAb-mediated effects on HIV-1 persistence and host immune responses.

Summary: Early clinical studies support additional evaluation of bNAbs. Antibodies may offer advantages over standard ART for HIV-1 prevention and therapy, and as components of immunologic strategies to achieve sustained virologic control. The evaluation of engineered bNAbs with multispecificity, extended half-lives and increased potency, as well as alternative bNAb-delivery systems are being pursued.

Citing Articles

Antibody prophylaxis may mask subclinical SIV infections in macaques.

Gonelli C, King H, Ko S, Fennessey C, Iwamoto N, Mason R Nature. 2025; 639(8053):205-213.

PMID: 39910294 PMC: 11882457. DOI: 10.1038/s41586-024-08500-y.

Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection.

Richel E, Cordsmeier A, Bauer L, Fraedrich K, Vestweber R, Roshani B PLoS Pathog. 2024; 20(12):e1012777.

PMID: 39724193 PMC: 11670951. DOI: 10.1371/journal.ppat.1012777.

Applying phylogenetic methods for species delimitation to distinguish B-cell clonal families.

Voss K, Kaur K, Banerjee R, Breden F, Pennell M Front Immunol. 2024; 15:1505032.

PMID: 39687606 PMC: 11646844. DOI: 10.3389/fimmu.2024.1505032.

Identification of antibody targets associated with lower HIV viral load and viremic control.

Grant-McAuley W, Morgenlander W, Ruczinski I, Kammers K, Laeyendecker O, Hudelson S PLoS One. 2024; 19(9):e0305976.

PMID: 39288118 PMC: 11407625. DOI: 10.1371/journal.pone.0305976.

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines.

Schwarzmuller M, Lozano C, Schanz M, Abela I, Grosse-Holz S, Epp S Cell Rep Med. 2024; 5(9):101702.

PMID: 39216479 PMC: 11524982. DOI: 10.1016/j.xcrm.2024.101702.

References

Scheid J, Mouquet H, Feldhahn N, Walker B, Pereyra F, Cutrell E . A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2008; 343(2):65-7. PMC: 2754789. DOI: 10.1016/j.jim.2008.11.012. View

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C . Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005; 11(6):615-22. DOI: 10.1038/nm1244. View

Padte N, Yu J, Huang Y, Ho D . Engineering multi-specific antibodies against HIV-1. Retrovirology. 2018; 15(1):60. PMC: 6114543. DOI: 10.1186/s12977-018-0439-9. View

Nishimura Y, Gautam R, Chun T, Sadjadpour R, Foulds K, Shingai M . Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017; 543(7646):559-563. PMC: 5458531. DOI: 10.1038/nature21435. View

Bournazos S, Wang T, Dahan R, Maamary J, Ravetch J . Signaling by Antibodies: Recent Progress. Annu Rev Immunol. 2017; 35:285-311. PMC: 5613280. DOI: 10.1146/annurev-immunol-051116-052433. View

Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K . Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016; 7:10844. PMC: 4782064. DOI: 10.1038/ncomms10844. View

Priddy F, Lewis D, Gelderblom H, Hassanin H, Streatfield C, LaBranche C . Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV. 2019; 6(4):e230-e239. PMC: 6443625. DOI: 10.1016/S2352-3018(19)30003-7. View

Gaudinski M, Coates E, Houser K, Chen G, Yamshchikov G, Saunders J . Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018; 15(1):e1002493. PMC: 5783347. DOI: 10.1371/journal.pmed.1002493. View

Cohen Y, Lorenzi J, Seaman M, Nogueira L, Schoofs T, Krassnig L . Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol. 2017; 92(5). PMC: 5809738. DOI: 10.1128/JVI.01883-17. View

10.

Lynch R, Boritz E, Coates E, DeZure A, Madden P, Costner P . Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015; 7(319):319ra206. DOI: 10.1126/scitranslmed.aad5752. View

11.

Mayer K, Seaton K, Huang Y, Grunenberg N, Isaacs A, Allen M . Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Med. 2017; 14(11):e1002435. PMC: 5685476. DOI: 10.1371/journal.pmed.1002435. View

12.

Klein F, Mouquet H, Dosenovic P, Scheid J, Scharf L, Nussenzweig M . Antibodies in HIV-1 vaccine development and therapy. Science. 2013; 341(6151):1199-204. PMC: 3970325. DOI: 10.1126/science.1241144. View

13.

Borducchi E, Liu J, Nkolola J, Cadena A, Yu W, Fischinger S . Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018; 563(7731):360-364. PMC: 6237629. DOI: 10.1038/s41586-018-0600-6. View

14.

Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K . Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017; 358(6359):85-90. PMC: 5978417. DOI: 10.1126/science.aan8630. View

15.

Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider E . Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017; 23(2):185-191. PMC: 5467219. DOI: 10.1038/nm.4268. View

16.

Bournazos S, Klein F, Pietzsch J, Seaman M, Nussenzweig M, Ravetch J . Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014; 158(6):1243-1253. PMC: 4167398. DOI: 10.1016/j.cell.2014.08.023. View

17.

Caskey M, Klein F, Nussenzweig M . Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019; 25(4):547-553. PMC: 7322694. DOI: 10.1038/s41591-019-0412-8. View

18.

Cohen Y, Lorenzi J, Krassnig L, Barton J, Burke L, Pai J . Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med. 2018; 215(9):2311-2324. PMC: 6122972. DOI: 10.1084/jem.20180936. View

19.

Gama L, Koup R . New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. Annu Rev Med. 2017; 69:409-419. DOI: 10.1146/annurev-med-061016-041032. View

20.

Caskey M, Klein F, Lorenzi J, Seaman M, West Jr A, Buckley N . Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015; 522(7557):487-91. PMC: 4890714. DOI: 10.1038/nature14411. View